Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

JL Lopez-Campos, C Calero-Acuña… - … Journal of Chronic …, 2017 - Taylor & Francis
Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
被引用次数：23 相关文章

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.

JL Lopez-Campos, C Calero-Acuña… - … Journal of Chronic …, 2017 - europepmc.org
Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β 2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
[PDF] scienceopen.com

[PDF][PDF] Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

J luis lopez-Campos… - International Journal of …, 2017 - scienceopen.com
Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

JL Lopez-Campos, C Calero-Acuña… - … Journal of Chronic …, 2017 - dovepress.com
Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β 2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
[PDF] semanticscholar.org

[PDF][PDF] Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

J luis lopez-Campos… - International Journal of …, 2017 - pdfs.semanticscholar.org
Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
[PDF] researchgate.net

[PDF][PDF] Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

J luis lopez-Campos… - International Journal of …, 2017 - researchgate.net
Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

JL Lopez-Campos, C Calero-Acuña… - … journal of chronic …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β 2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
[HTML] nih.gov

[HTML][HTML] Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

JL Lopez-Campos, C Calero-Acuña… - … Journal of Chronic …, 2017 - ncbi.nlm.nih.gov
Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β 2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

JL Lopez-Campos, C Calero-Acuna… - International Journal of …, 2017 - go.gale.com
Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
[[beta]. sub. 2]-agonist (LABA) in a single inhaler is a viable treatment option for patients with …
[PDF] researchgate.net

[PDF][PDF] Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

J luis lopez-Campos… - International Journal of …, 2017 - researchgate.net
Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …